On the stock market since 2019, it operates in the world of health and science. It has 2,442 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 71% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $543.1M. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 54% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 65% a year on average.
This stock swings about 2.3 times as much as the market average. Big rallies — and big drops — can both happen fast.
The company’s market value is 57 times its annual profit. Even a small disappointment could hit the price hard.
The stock trades 11% above the average analyst price target.
On our five-subject report card, HIMS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HIMS is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.